Global use of Haemophilus influenzae type b conjugate vaccine.
Haemophilus influenzae type b (Hib) conjugate vaccines have been underutilized globally. We report progress in global use of Hib vaccines included in national immunization schedules. The number of countries using Hib vaccine increased from 89/193 (46%) in 2004 to 158/193 (82%) by the end of 2009. The increase was greatest among low-income countries eligible for financial support from the GAVI Alliance [13/75 (17%) in 2004, 60/72 (83%) by the end of 2009], and can be attributed to various factors. Additional efforts are still needed to increase vaccine adoption in lower middle income countries [20/31 (65%) by the end of 2009].
Ojo
Linda R
LR
Respiratory Diseases Branch, Division of Bacterial Diseases, Centers for Disease Control and Prevention, 1600 Clifton Road NE, MS C-23, Atlanta, GA 30333, USA.
O'Loughlin
Rosalyn E
RE
Cohen
Adam L
AL
Loo
Jennifer D
JD
Edmond
Karen M
KM
Shetty
Sharmila S
SS
Bear
Allyson P
AP
Privor-Dumm
Lois
L
Griffiths
Ulla K
UK
Hajjeh
Rana
R
D016667:Bacterial Capsules / Q000008:administration & dosage*; D003906:Developing Countries; D006192:Haemophilus Infections / Q000276:immunology / Q000517:prevention & control; D018073:Haemophilus Vaccines / Q000008:administration & dosage*; D006801:Humans; D017589:Immunization Programs / Q000706:statistics & numerical data*; D055818:Public-Private Sector Partnerships; D014611:Vaccination / Q000706:statistics & numerical data*; D018074:Vaccines, Conjugate / Q000008:administration & dosage; D014944:World Health Organization
D018073:Haemophilus Vaccines; C044237:Haemophilus influenzae type b polysaccharide vaccine; D018074:Vaccines, Conjugate